{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:15:45Z","timestamp":1788315345086,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01172-6","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:26:19Z","timestamp":1781947579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR8554, a biased \u00b5-opioid receptor agonist: a phase I trial in healthy volunteers"],"prefix":"10.1186","volume":"27","author":[{"given":"Lifang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/1471-2458-11-770","volume":"11","author":"DS Goldberg","year":"2011","unstructured":"Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770.","journal-title":"BMC Public Health"},{"issue":"19","key":"1172_CR2","doi-asserted-by":"publisher","first-page":"e25929","DOI":"10.1097\/MD.0000000000025929","volume":"100","author":"F Yao","year":"2021","unstructured":"Yao F, et al. Patient activation level and its associated factors in adults with chronic pain: A cross-sectional survey. Med (Baltim). 2021;100(19):e25929.","journal-title":"Med (Baltim)"},{"issue":"2","key":"1172_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/rapm-2024-105964","volume":"50","author":"A Tassou","year":"2025","unstructured":"Tassou A, Richebe P, Rivat C. Mechanisms of chronic postsurgical pain. Reg Anesth Pain Med. 2025;50(2):77\u201385.","journal-title":"Reg Anesth Pain Med"},{"key":"1172_CR4","doi-asserted-by":"crossref","unstructured":"He Y, et al. Historical perspectives and recent advances in small molecule ligands of selective\/biased\/multi-targeted \u00b5\/\u03b4\/\u03ba opioid receptor (2019-2022). Bioorg Chem. 2023;141:106869.","DOI":"10.1016\/j.bioorg.2023.106869"},{"key":"1172_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","volume":"63","author":"E Kelly","year":"2023","unstructured":"Kelly E, Conibear A, Henderson G. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists. Annu Rev Pharmacol Toxicol. 2023;63:491\u2013515.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"106961","DOI":"10.1016\/j.phrs.2023.106961","volume":"197","author":"N Ramos-Gonzalez","year":"2023","unstructured":"Ramos-Gonzalez N, Paul B, Majumdar S. IUPHAR themed review: Opioid efficacy, bias, and selectivity. Pharmacol Res. 2023;197:106961.","journal-title":"Pharmacol Res"},{"issue":"11","key":"1172_CR7","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14740338.2021.1965989","volume":"20","author":"HS Tan","year":"2021","unstructured":"Tan HS, Habib AS. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain. Expert Opin Drug Saf. 2021;20(11):1291\u20138.","journal-title":"Expert Opin Drug Saf"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"111870","DOI":"10.1016\/j.jclinane.2025.111870","volume":"105","author":"DI Sessler","year":"2025","unstructured":"Sessler DI, et al. Oliceridine for postoperative pain and opioid-related complications: The intravenous oliceridine and opioid-related complications (VOLITION) prospective cohort study. J Clin Anesth. 2025;105:111870.","journal-title":"J Clin Anesth"},{"issue":"4","key":"1172_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1172_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cpt.1643","volume":"107","author":"C Nofziger","year":"2020","unstructured":"Nofziger C, et al. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020;107(1):154\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1172_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s11864-022-01010-x","volume":"23","author":"AK Wong","year":"2022","unstructured":"Wong AK, et al. The Role of Pharmacogenomics in Opioid Prescribing. Curr Treat Options Oncol. 2022;23(10):1353\u201369.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"1172_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11916-018-0666-8","volume":"22","author":"DJ Pak","year":"2018","unstructured":"Pak DJ, et al. Chronification of Pain: Mechanisms, Current Understanding, and Clinical Implications. Curr Pain Headache Rep. 2018;22(2):9.","journal-title":"Curr Pain Headache Rep"},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.2147\/DDDT.S525471","volume":"19","author":"K Yi","year":"2025","unstructured":"Yi K, et al. Overview and Prospects of the Clinical Application of Oliceridine. Drug Des Devel Ther. 2025;19:5415\u201330.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"1172_CR14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1213\/ANE.0000000000003662","volume":"129","author":"DY Liang","year":"2019","unstructured":"Liang DY, et al. Pharmacological Characters of Oliceridine, a \u00b5-Opioid Receptor G-Protein-Biased Ligand in Mice. Anesth Analg. 2019;129(5):1414\u201321.","journal-title":"Anesth Analg"},{"issue":"1","key":"1172_CR15","doi-asserted-by":"publisher","first-page":"22635","DOI":"10.1038\/s41598-025-98697-3","volume":"15","author":"L Huang","year":"2025","unstructured":"Huang L, et al. Exploring Pharmacokinetic interactions between SHR8554, a \u00b5-opioid receptor biased agonist, and Itraconazole in healthy Chinese subjects. Sci Rep. 2025;15(1):22635.","journal-title":"Sci Rep"},{"key":"1172_CR16","doi-asserted-by":"publisher","first-page":"115192","DOI":"10.1016\/j.fct.2024.115192","volume":"196","author":"PJ Ferron","year":"2025","unstructured":"Ferron PJ, et al. Role of CYP2D6 polymorphisms in tramadol metabolism in a context of co-medications and overweight. Food Chem Toxicol. 2025;196:115192.","journal-title":"Food Chem Toxicol"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2147\/DDDT.S199574","volume":"13","author":"J Lee","year":"2019","unstructured":"Lee J, et al. Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6. Drug Des Devel Ther. 2019;13:1751\u201361.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"1172_CR18","doi-asserted-by":"publisher","first-page":"e2523543","DOI":"10.1001\/jamanetworkopen.2025.23543","volume":"8","author":"NA Nahid","year":"2025","unstructured":"Nahid NA, et al. CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment. JAMA Netw Open. 2025;8(7):e2523543.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01172-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01172-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:36:08Z","timestamp":1788312968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01172-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01172-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Drug Clinical Trial Ethics Committee of the Second Affiliated Hospital, Zhejiang University School of Medicine. The study was conducted in accordance with local legislation and institutional requirements. Written informed consent was obtained from all participants prior to enrollment.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Min Yan reports receiving research grants from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Min Yan reports receiving research grants from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}